Business Context and Reporting Period
This Form 8-K is a current report filed by Dermata Therapeutics, Inc. on June 4, 2024. The filing addresses a specific corporate governance event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency:
- Previous Status: On November 15, 2023, the company was notified of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock closing bid price falling below $1.00 for 30 consecutive business days.
- Extension: On May 14, 2024, the company was granted a 180-day extension to regain compliance.
- Current Status: On June 4, 2024, Nasdaq confirmed the company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk addressed was the potential delisting due to low stock price, which has been mitigated by the restoration of compliance. No other contingencies or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of common stock (DRMA) and warrants (DRMAW) on The Nasdaq Capital Market.
- Confirm that no further correspondence from Nasdaq regarding listing standards is pending.
- Review the company's most recent 10-Q or 10-K for financial metrics, as this 8-K does not contain financial data.